Acumen Pharmaceuticals (ABOS) Competitors

$2.39 -0.10 (-4.02%)

Closing price 04:00 PM Eastern

Extended Trading

$2.38 -0.01 (-0.21%)

As of 06:44 PM Eastern

ABOS vs. AVTE, CTMX, SLDB, TLRY, and ARVN

Should you buy Acumen Pharmaceuticals stock or one of its competitors? MarketBeat compares Acumen Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acumen Pharmaceuticals include Aerovate Therapeutics (AVTE), CytomX Therapeutics (CTMX), Solid Biosciences (SLDB), Tilray Brands (TLRY), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry.

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A

In the previous week, Acumen Pharmaceuticals had 10 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 10 mentions for Acumen Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Acumen Pharmaceuticals' average media sentiment score of 0.55 beat Aerovate Therapeutics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Acumen Pharmaceuticals	Positive

Aerovate Therapeutics' return on equity of -90.19% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Acumen Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 178.94%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Summary

Acumen Pharmaceuticals beats Aerovate Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to CytomX Therapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 9.3% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CytomX Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A
CytomX Therapeutics	$76.20M	8.44	-$17.37M	-$0.41	N/A

In the previous week, CytomX Therapeutics had 9 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 19 mentions for CytomX Therapeutics and 10 mentions for Acumen Pharmaceuticals. CytomX Therapeutics' average media sentiment score of 0.75 beat Acumen Pharmaceuticals' score of 0.55 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Acumen Pharmaceuticals has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

Acumen Pharmaceuticals currently has a consensus target price of $6.67, indicating a potential upside of 178.94%. CytomX Therapeutics has a consensus target price of $12.78, indicating a potential upside of 238.04%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Acumen Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market.

Summary

CytomX Therapeutics beats Acumen Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Solid Biosciences is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A

Solid Biosciences has a beta of 2.47, indicating that its share price is 147% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 1.9% of Solid Biosciences shares are owned by insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Solid Biosciences presently has a consensus target price of $16.36, suggesting a potential upside of 114.46%. Acumen Pharmaceuticals has a consensus target price of $6.67, suggesting a potential upside of 178.94%. Given Acumen Pharmaceuticals' higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 10 mentions for Acumen Pharmaceuticals and 8 mentions for Solid Biosciences. Acumen Pharmaceuticals' average media sentiment score of 0.55 beat Solid Biosciences' score of -0.31 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences' return on equity of -73.42% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Summary

Solid Biosciences beats Acumen Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Tilray Brands?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Acumen Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market.

Acumen Pharmaceuticals has higher earnings, but lower revenue than Tilray Brands. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A
Tilray Brands	$821.31M	0.78	-$2.19B	-$13.65	N/A

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 9.4% of Tilray Brands shares are held by institutional investors. 9.3% of Acumen Pharmaceuticals shares are held by company insiders. Comparatively, 0.8% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Tilray Brands had 4 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 14 mentions for Tilray Brands and 10 mentions for Acumen Pharmaceuticals. Tilray Brands' average media sentiment score of 0.81 beat Acumen Pharmaceuticals' score of 0.55 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Tilray Brands	7 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acumen Pharmaceuticals currently has a consensus target price of $6.67, suggesting a potential upside of 178.94%. Tilray Brands has a consensus target price of $11.50, suggesting a potential upside of 109.09%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Acumen Pharmaceuticals is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Acumen Pharmaceuticals has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Tilray Brands	-156.51%	-3.31%	-2.42%

Summary

Acumen Pharmaceuticals and Tilray Brands tied by winning 7 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Arvinas?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Acumen Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Acumen Pharmaceuticals has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Arvinas	-247.54%	-44.38%	-28.38%

Arvinas has higher revenue and earnings than Acumen Pharmaceuticals. Arvinas is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A
Arvinas	$262.60M	2.31	-$80.80M	-$3.32	N/A

In the previous week, Arvinas had 16 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 26 mentions for Arvinas and 10 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.55 beat Arvinas' score of 0.49 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	11 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 9.3% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 7.3% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Acumen Pharmaceuticals currently has a consensus target price of $6.67, suggesting a potential upside of 178.94%. Arvinas has a consensus target price of $15.14, suggesting a potential upside of 60.75%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Acumen Pharmaceuticals is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Arvinas	3 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Arvinas beats Acumen Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Acumen Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABOS vs. The Competition

Export

Metric	Acumen Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$179.85M	$3.42B	$6.34B	$12.38B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-1.28	10.64	17.79	23.07
Price / Sales	N/A	293.55	549.57	79.28
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	1.98	6.93	9.93	6.96
Net Income	-$121.33M	$24.11M	$3.55B	$333.52M
7 Day Performance	-3.24%	0.08%	-0.33%	0.45%
1 Month Performance	-10.82%	0.84%	1.34%	4.06%
1 Year Performance	143.88%	78.10%	41.10%	36.24%

Acumen Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABOS Acumen Pharmaceuticals	2.2266 of 5 stars	$2.39 -4.0%	$6.67 +178.9%	+137.1%	$179.85M	N/A	N/A	20	News Coverage Earnings Report
AVTE Aerovate Therapeutics	N/A	$24.52 +1.2%	N/A	+194.1%	$710.71M	N/A	N/A	20	High Trading Volume
CTMX CytomX Therapeutics	2.7884 of 5 stars	$4.09 -2.3%	$13.44 +229.1%	+51.6%	$695.21M	$76.20M	N/A	170	Trending News Earnings Report Analyst Forecast Analyst Revision
SLDB Solid Biosciences	2.9107 of 5 stars	$6.82 -5.7%	$16.09 +135.9%	+164.5%	$671.18M	N/A	N/A	100	News Coverage Earnings Report Analyst Forecast
TLRY Tilray Brands	3.5481 of 5 stars	$5.72 -3.1%	$11.50 +101.2%	+21.2%	$665.96M	$210.48M	N/A	2,842

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABOS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. AVTE, CTMX, SLDB, TLRY, and ARVN

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to CytomX Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to Solid Biosciences?

Summary

How does Acumen Pharmaceuticals compare to Tilray Brands?

Summary

How does Acumen Pharmaceuticals compare to Arvinas?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. AVTE, CTMX, SLDB, TLRY, and ARVN

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Which has better valuation & earnings, AVTE or ABOS?

Does the media prefer AVTE or ABOS?

Is AVTE or ABOS more profitable?

Do analysts prefer AVTE or ABOS?

Do institutionals & insiders believe in AVTE or ABOS?

Which has more volatility & risk, AVTE or ABOS?

Summary

How does Acumen Pharmaceuticals compare to CytomX Therapeutics?

Do institutionals and insiders believe in ABOS or CTMX?

Which has higher earnings & valuation, ABOS or CTMX?

Does the media refer more to ABOS or CTMX?

Is ABOS or CTMX more profitable?

Do analysts recommend ABOS or CTMX?

Which has more volatility & risk, ABOS or CTMX?

Summary

How does Acumen Pharmaceuticals compare to Solid Biosciences?

Which has preferable valuation & earnings, SLDB or ABOS?

Which has more risk and volatility, SLDB or ABOS?

Do institutionals & insiders have more ownership in SLDB or ABOS?

Do analysts prefer SLDB or ABOS?

Does the media prefer SLDB or ABOS?

Is SLDB or ABOS more profitable?

Summary

How does Acumen Pharmaceuticals compare to Tilray Brands?

Which has more volatility & risk, ABOS or TLRY?

Which has stronger valuation and earnings, ABOS or TLRY?

Do institutionals and insiders have more ownership in ABOS or TLRY?

Does the media favor ABOS or TLRY?

Do analysts recommend ABOS or TLRY?

Is ABOS or TLRY more profitable?

Summary

How does Acumen Pharmaceuticals compare to Arvinas?

Which has more risk & volatility, ABOS or ARVN?

Is ABOS or ARVN more profitable?

Which has preferable earnings and valuation, ABOS or ARVN?

Does the media refer more to ABOS or ARVN?

Do insiders & institutionals have more ownership in ABOS or ARVN?

Do analysts recommend ABOS or ARVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools